PREVALENCE OF CARBAPENEM RESISTANT ENTEROBACTERIACEAEINFECTIONS, THEIR MANAGEMENT AND OUTCOME AMONG CANCER PATIENTS.
European Journal of Molecular & Clinical Medicine,
2021, Volume 8, Issue 3, Pages 4784-4791
AbstractPurpuse:This study aims to evaluatethe prevalence of CRE (Carbapenem-resistant Enterobacteriaceae) infectionsamong cancer patients, their characterization, and follow-up of the patients to know the outcome.
Method:For one year from August 2018 to July 2019 samples of two hundred and forty-two non-duplicate clinical specimens were obtained from patients at our centre.Clinical and demographic data and clinical outcome are gatheredfrom the electronic hospital medical records. Any significant growth from any source was processed for microbial identification and susceptibility by Vitek 2 Compact. Phenotypic confirmation of carbapenemase production was done as per CLSI (Clinical & Laboratory Standards Institute) guidelines using eCIM (EDTA- modified carbapenem inactivation method) andmCIM (modified carbapenem inactivation method).
Result: A total of 88 gram-negative isolates were isolated. Escherichia coli(53.4%) was the main Gram-negative isolate from all samples followed by Pseudomonas aeruginosa (21.5%). Among the Gram-negative Enterobacteriaceae (n=67) isolates, 31.3% were carbapenem-resistant. None was isolated from blood cultures.The average length of stay of CRE-infected patients was 10.33 days as compared to those not infected with CRE (5.4 days). The average cost of management per admission wassignificantly higher in patients with CRE infection.
Conclusion: This study provides abaseline data on the prevalence of CRE among people suffering from cancer in Central India along with its outcome, which might be helpful for better implementation of antimicrobial, diagnostic, and infection control stewardship.
- Article View: 152
- PDF Download: 178